Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- How Will FDA Ruling Affect Eli Lilly's Effient?
- Mike Huckman submits: I don't think Eli Lilly LLY will be running any more "Coming Soon" ads--like the one posted here for its late-stage experimental bloodthinner Effient--for drugs that haven't been approved yet by the Food and Drug Administration. Given the unpredictable nature of the agency and its...
- External links 2008-10-19
- Roche: Why No News About Genentech from Earnings Call?
- Mike Huckman submits: Genentech DNA investors who were hoping Roche (RHHBY.PK) would shed a little more light on the status of its proposed acquisition of the biotech giant might have hung up from the Swiss drugmaker's conference call a little disappointed. But apparently Roche, which trades on the Swiss...
- External links 2008-10-22
- Will Merck's Job Cuts Help the Company?
- Mike Huckman submits: You gotta feel sorry for the folks at Merck MRK. Immediately after the drugmaker finishes a program to get rid of more than 10,000 employees, the company drops the axe again. This time 7,200 people (12 percent of its workforce) will be let go by the...
- External links 2008-10-22
- Merck Goes Back to School to Push HPV Vaccination
- Mike Huckman submits: As a reporter, you never know when or where you might stumble on a story—or at least a blog entry. There I was Wednesday guest lecturing for an old friend's TV-news production class at my alma mater. So, while at the USC Annenberg School of Communications,...
- External links 2008-10-31
- Merck Rolls the Dice on New Januvia Study
- Mike Huckman submits: The drug company that got into so much trouble when it uncovered and/or disclosed a cardiovascular side-effect of a popular painkiller Vioxx is launching a huge study to see if an up-and-coming diabetes drug is also bad for the heart. In a research note to clients...
- External links 2008-11-15
- Will Carl Icahn Come to Amylin's Rescue?
- Mike Huckman submits: Wall Street has essentially thrown in the towel lately on Amylin Pharmaceuticals AMLN. The shares have plummeted from nearly $30 just three months ago to around $7 yesterday. But billionaire activist investor Carl Icahn apparently sees the stock as being on sale. At the end...
- External links 2008-11-17
- Novo Nordisk: Approval of New Diabetes Drug Is Further Postponed
- Mike Huckman submits: Novo Nordisk NVO, a company that has a vested interest in the diabetes market, is out with a new report pegging the cost of treating the disease at nearly a quarter-trillion dollars. According to the "National Changing Diabetes Program" which is sponsored by NVO, the...
- External links 2008-11-18
- Finally, A Look at Schering-Plough's Pipeline
- Mike Huckman submits: Schering-Plough SGP raised the curtain Monday on its drug development pipeline for the first time in three years and analysts, for the most part, liked what they saw. Investors are responding to a slew of bullish research notes out Tuesday morning and are sending SGP shares...
- External links 2008-11-25
- Roche Says It'll Still Buy Genentech, Investors Think Otherwise
- Mike Huckman submits: Yesterday morning, the mining company BHP Billiton BHP threw in the towel on its year-and-a-half long hostile attempt to buy its rival Rio Tinto RTP. The company cited the global economy and commodity prices for the pullout. On the heels of that announcement, a reporter from...
- External links 2008-11-25
- Short Interests in Pfizer and Dendreon Decline - Is Bearish Sentiment Dissipating?
- Mike Huckman submits: I know that simply pointing this out will draw the ire of certain Pfizer PFE investors who happen to read my blog, but the fact is that PFE is the only major pharmaceutical company whose short interest is big enough to crack the Barron's Top-40. PFE...
- External links 2008-12-03
- Surprise, Pfizer Study Says Lipitor Beats Generic Zocor
- Mike Huckman submits: CNBC.comTuesday afternoon the "Journal of the American Medical Association" (JAMA) published a study showing that cheaper, generic heart drugs work just as well as more expensive, brand-name heart drugs. by Mike Huckman
- External links 2008-12-03
- Is Merck a Drug Spending Bellwether?
- Mike Huckman submits: Earlier this week UBS pharmaceutical analyst Roopesh Patel put out a big 2009 sector outlook research note claiming, "So far, the global economic slowdown has had no noticeable impact — a) U.S. weekly and monthly U.S. prescription trends are stable; b) there also is no meaningfully...
- External links 2008-12-05
- Merck and Eli Lilly Maintain Analyst Ratings
- Mike Huckman submits: Analysts have a one-day respite between two major pharma R & D days and they're using it to size up Merck's MRK update Tuesday and to set expectations for Eli Lilly's LLY briefing today. Again, I'll be at the Lilly meeting in New York City where...
- External links 2008-12-10
- Bristol Talks the Talk in Mandarin
- Mike Huckman submits: I was all set to write a blog today about Bristol-Myers Squibb BMY and a little-known company called Exelixis EXEL becoming the latest pharma-biotech hookup. Bristol-Myers Squibb is giving Exelixis nearly $200 million cash money up front to buy into a couple of cancer drugs. ...
- External links 2008-12-13
- Is Pfizer Now Interested in a Merger?
- Mike Huckman submits: AP The "Financial Times" apparently got a one-on-one interview with Pfizer PFE Chairman and CEO Jeff Kindler and is playing up what he said with the headline, "Pfizer eyes merger deal with large rival." That conclusion is based on this quote: "We are open to opportunities and...
- External links 2009-01-05
- Ladies Still in Waiting for Merck's Gardasil
- Mike Huckman submits: The FDA giveth and the FDA taketh away. Thursday the agency handed Merck MRK a little bit of a break with what could be interpreted as an endorsement, of sorts, of the cholesterol drug Vytorin that MRK shares with Schering-Plough SGP. Financially though, the pill...
- External links 2009-01-10
- JNJ Hurt by Soft Stent Sales
- Mike Huckman submits: CNBC.comDow component and giant healthcare company--you really can't lump it in with big pharma because it sells drugs, medical devices and consumer products--Johnson & Johnson JNJ reported earnings Tuesday morning. JNJ beat on the bottom line, missed on the top line and provided 2009 earnings...
- External links 2009-01-20
- Lilly and Glaxo's Musical Chairs
- Mike Huckman submits: I laughed out loud in my car on the way to work this morning. At 8:07 a.m. ET this press release from Eli Lilly LLY showed up on my BlackBerry. Yeah, I confess to reading it while driving. And, yeah, I know that especially as the...
- External links 2009-01-30
- Why the Drop in Roche's Genentech Bid?
- Mike Huckman submits: Genentech DNA shares dropped three percent Friday or $2.85 to $81.24 after Roche showed some chutzpah and lowered its bid for DNA. Recently, there'd been reports that the Swiss drugmaker, which already has a majority stake in the California biotech, was going to raise the offer...
- External links 2009-02-01
- Pfizer Scraps Pancreatic Cancer Drug
- Mike Huckman submits: So, what do you do at the end of a week where your company's stock was the worst performer in the Dow and you've got some bad news that could make the shares go down even more? You employ one of the oldest PR tricks in...
- External links 2009-02-03
- << Previous
- page 1 of 3
- Next >>
